Gold drug auranofin restricts the viral reservoir in the monkey AIDS model and induces containment of viral load following ART suspension

AIDS

Volumn 25, Issue 11, 2011, Pages 1347-1356

  Lewis, Mark G ^a   Dafonseca, Sandrina ^b   Chomont, Nicolas ^b   Palamara, Anna T ^c,d   Tardugno, Maria ^c   Mai, Antonello ^c   Collins, Matt ^a   Wagner, Wendeline L ^a   Yalley Ogunro, Jake ^a   Greenhouse, Jack ^a   Chirullo, Barbara ^e   Norelli, Sandro ^e   Garaci, Enrico ^e   Savarino, Andrea ^e  

^a BIOQUAL INC   (United States)

^b VGTI Florida   (United States)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d IRCCS SAN RAFFAELE PISANA   (Italy)

^e ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

central memory; eradication; remission; reservoir; SIVmac251; therapy suspension; viral DNA

Indexed keywords

AURANOFIN; DARUNAVIR; EMTRICITABINE; RALTEGRAVIR; RITONAVIR; TENOFOVIR; VIRUS DNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CELL COMPARTMENTALIZATION; CELL DEATH; CELL DIFFERENTIATION; CELL SUBPOPULATION; CELL VIABILITY; CONTROLLED STUDY; DISEASE CARRIER; FLOW CYTOMETRY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LENTIVIRUS INFECTION; MEMORY T LYMPHOCYTE; NONHUMAN; PHENOTYPE; PILOT STUDY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REMISSION; RHESUS MONKEY; VIRUS LOAD;

ANIMALS; ANTI-RETROVIRAL AGENTS; ANTIRHEUMATIC AGENTS; AURANOFIN; CD4-POSITIVE T-LYMPHOCYTES; DNA, VIRAL; MACACA MULATTA; PILOT PROJECTS; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; TREATMENT OUTCOME; VIRAL LOAD; VIRUS LATENCY; VIRUS REPLICATION;

EID: 79960014190     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328347bd77     Document Type: Article

References (48)

1. Colin L, Van Lint C. Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology 2009; 6:111.
2. Trono D, Van Lint C, Rouzioux C, Verdin E, Barré-Sinoussi F, Chun TW, Chomont N. HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science 2010; 329:174-180.
3. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 1997; 94:13193-13197. (Pubitemid 27518498)
4. Chun TW, Justement JS, Pandya P, Hallahan CW, McLaughlin M, Liu S, et al. Relationship between the size of the human immunodeficiency virus type 1 (HIV-1) reservoir in peripheral blood CD4T cells and CD4:CD8R T cell ratios in aviremic HIV-1-infected individuals receiving long-term highly active antiretroviral therapy. J Infect Dis 2002; 185:1672-1676. (Pubitemid 34587533)
5. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278:1295-1300. (Pubitemid 27495742)
6. Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, et al. HIV reservoir size and persistence are driven by T-cell survival and homeostatic proliferation. Nat Med 2009; 15:893-900.
7. Fritsch RD, Shen X, Sims GP, Hathcock KS, Hodes RJ, Lipsky PE. Stepwise differentiation of CD4 memory T cells defined by expression of CCR7 and CD27. J Immunol 2005; 175:6489-6497. (Pubitemid 41598891)
8. Zielinski CE, Corti D, Mele F, Pinto D, Lanzavecchia A, Sallusto F. Dissecting the human immunologic memory for pathogens. Immunol Rev 2011; 240:40-51.
9. Okada R, Kondo T, Matsuki F, Takata H, Takiguchi M. Phenotypic classification of human CD4T cell subsets and their differentiation. Int Immunol 2008; 20:1189-1199.
10. Hendriks J, Xiao Y, Borst J. CD27 promotes survival of activated T cells and complements CD28 in generation and establishment of the effector T cell pool. J Exp Med 2003; 198:1369-1380. (Pubitemid 37392482)
11. Hendriks J, Gravestein LA, Tesselaar K, van Lier RA, Schumacher TN, Borst J. CD27 is required for generation and long-term maintenance of T cell immunity. Nat Immunol 2000; 1:433-440.
12. Riou C, Yassine-Diab B, Van Grevenynghe J, Somogyi R, Greller LD, Gagnon D, et al. Convergence of TCR and cytokine signaling leads to FOXO3a phosphorylation and drives the survival of CD4 central memory T cells. J Exp Med 2007; 204:79-91. (Pubitemid 46148759)
13. van Oosterwijk MF, Juwana H, Arens R, Tesselaar K, van Oers MH, Eldering E, et al. CD27-CD70 interactions sensitise naive CD4T cells for IL-12-induced Th1 cell development. Int Immunol 2007; 19:713-718. (Pubitemid 47078715)
14. Hü tter G, Nowak D, Mossner M, Ganepola S, Mü ssig A, Allers K, et al. Long-term control of HIV by CCR5Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009; 360:692-698.
15. Hamer DH. Can HIV be cured? Mechanisms of HIV persistence and strategies to combat it. Curr HIV Res 2004; 2:99-111. (Pubitemid 38854925)
16. Savarino A, Mai A, Norelli S, El Daker S, Valente S, Rotili D, et al. Shock and kill' effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence. Retrovirology 2009; 6:52.
17. Eisler R. Chrysotherapy: a synoptic review. Inflamm Res 2003; 52:487-501. (Pubitemid 38058223)
18. Maldonado A, Mueller YM, Thomas P, Bojczuk P, O'Connors C, Katsikis PD. Decreased effector memory CD45RAR CD62LCD8R T cells and increased central memory CD45RACD62LR CD8R T cells in peripheral blood of rheumatoid arthritis patients. Arthritis Res Ther 2003; 5:R91-R96.
19. Dalziel K, Going G, Cartwright PH, Marks R, Beveridge GW, Rowell NR. Treatment of chronic discoid lupus erythematosus with an oral gold compound (auranofin). Br J Dermatol 1986; 115:211-216. (Pubitemid 16069466)
20. Kean WF, Hart L, Buchanan WW. Auranofin. Br J Rheumatol 1997; 36:560-572.
21. Hashimoto K, Whitehurst CE, Lipsky PE. Synergistic inhibition of T cell proliferation by gold sodium thiomalate and auranofin. J Rheumatol 1994; 21:1020-1026. (Pubitemid 24182271)
22. Han S, Kim K, Kim H, Kwon J, Lee YH, Lee CK, et al. Auranofin inhibits overproduction of pro-inflammatory cytokines, cyclooxygenase expression and PGE2 production in macrophages. Arch Pharm Res 2008; 31:67-74.
23. Kim TS, Kang BY, Lee MH, Choe YK, Hwang SY. Inhibition of interleukin-12 production by auranofin, an antirheumatic gold compound, deviates CD4(R) T cells from the Th1 to the Th2 pathway. Br J Pharmacol 2001; 134:571-578. (Pubitemid 32977901)
24. Rigobello MP, Folda A, Dani B, Menabò R, Scutari G, Bindoli A. Gold(I) complexes determine apoptosis with limited oxidative stress in Jurkat T cells. Eur J Pharmacol 2008; 582:26-34.
25. Cox AG, Brown KK, Arner ES, Hampton MB. The thioredoxin reductase inhibitor auranofin triggers apoptosis through a Bax/ Bak-dependent process that involves peroxiredoxin 3 oxidation. Biochem Pharmacol 2008; 76:1097-1109.
26. Hafejee A, Winhoven S, Coulson IH. Jessner's lymphocytic infiltrate responding to oral auranofin. J Dermatolog Treat 2004; 15:331-332. (Pubitemid 39423294)
27. Shapiro DL, Masci JR. Treatment of HIV associated psoriatic arthritis with oral gold. J Rheumatol 1996; 10:1818-1820. (Pubitemid 26342461)
28. Park SJ, Kim M, Kim NH, Oh MK, Cho JK, Jin JY, Kim IS. Auranofin promotes retinoic acid-or dihydroxyvitamin D3-mediated cell differentiation of promyelocytic leukaemia cells by increasing histone acetylation. Br J Pharmacol 2008; 154:1196-1205. (Pubitemid 351992066)
29. Lewis MG, Norelli S, Collins M, Barreca ML, Iraci N, Chirullo B, et al. Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy. Retrovirology 2010; 7:21.
30. Mai A, Esposito M, Sbardella G, Massa S. A new facile and expeditious synthesis of /N/-hydroxy-/N(/-phenyloctanediamide, a potent inducer of terminal cytodifferentiation. Org Prep Proced Int 2001; 33:391-394.
31. Pitcher CJ, Hagen SI, Walker JM, Lum R, Mitchell BL, Maino VC, et al. Development and homeostasis of T cell memory in rhesus macaque. J Immunol 2002; 168:29-43. (Pubitemid 34014099)
32. Lewis D, Capell HA, McNeil CJ, Iqbal MS, Brown DH, Smith WE. Gold levels produced by treatment with auranofin and sodium aurothiomalate. Ann Rheum Dis 1983; 42:566-570. (Pubitemid 13016032)
33. Kim IS, Jin JY, Lee IH, Park SJ. Auranofin induces apoptosis and when combined with retinoic acid enhances differentiation of acute promyelocytic leukaemia cells in vitro. Br J Pharmacol 2004; 142:749-755. (Pubitemid 38969669)
34. Yukl S, Sinclair E, Epling L, Li Q, Shergill A, McQuaid K, et al. CD4R T cell reconstitution, T cell activation, and memory T cell subset composition in blood and gut of HIV-negative and ART-suppressed HIV-positive patients: implications for HIV persistence in the gut. J Int AIDS Soc 2010; 13 (Suppl 3):O1.
35. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, et al. Positive effects of combined antiretroviral therapy on CD4R T cell homeostasis and function in advanced HIV disease. Science 1997; 277:112-116. (Pubitemid 27450659)
36. Bourry O, Mannioui A, Sellier P, Roucairol C, Durand-Gasselin L, Dereuddre-Bosquet N, et al. Effect of a short-term HAART on SIV load in macaque tissues is dependent on time of initiation and antiviral diffusion. Retrovirology 2010; 7:78.
37. Groot F, van Capel TM, Schuitemaker J, Berkhout B, de Jong EC. Differential susceptibility of näve, central memory and effector memory T cells to dendritic cell-mediated HIV-1 transmission. Retrovirology 2006; 3:52.
38. Angel JB, Routy JP, Tremblay C, Ayers D, Woods R, Singer J, et al. A randomized controlled trial of HIV therapeutic vaccination using ALVAC with or without Remune. AIDS 2011 [Epub ahead of print].
39. Cervasi B, Paiardini M, Serafini S, Fraternale A, Menotta M, Engram J, et al. Administration of fludarabine-loaded autologous red blood cells in simian immunodeficiency virus-infected sooty mangabeys depletes pSTAT-1-expressing macrophages and delays the rebound of viremia after suspension of antiretroviral therapy. J Virol 2006; 80:10335-10345. (Pubitemid 44628881)
40. Cafaro A, Bellino S, Titti F, Maggiorella MT, Sernicola L, Wiseman RW, et al. Impact of viral dose and major histocompatibility complex class IB haplotype on viral outcome in mauritian cynomolgus monkeys vaccinated with Tat upon challenge with simian/human immunodeficiency virus SHIV89.6P. J Virol 2010; 84:8953-8958.
41. Margolick JB, Gange SJ, Detels R, O'Gorman MR, Rinaldo CR Jr, Lai S. Impact of inversion of the CD4/CD8 ratio on the natural history of HIV-1 infection. J Acquir Immune Defic Syndr 2006; 42:620-626. (Pubitemid 44162434)
42. Hocqueloux L, Prazuck T, Avettand-Fenoel V, Lafeuillade A, Cardon B, Viard JP, Rouzioux C. Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection. AIDS 2010; 24:1598-1601.
43. Lori F, Lewis MG, Xu J, Varga G, Zinn DE Jr, Crabbs C, et al. Control of SIV rebound through structured treatment interruptions during early infection. Science 2000; 290: 1591-1593.
44. Benlhassan-Chahour K, Penit C, Dioszeghy V, Vasseur F, Janvier G, Rivière Y, et al. Kinetics of lymphocyte proliferation during primary immune response in macaques infected with pathogenic simian immunodeficiency virus SIVmac251: preliminary report of the effect of early antiviral therapy. J Virol 2003; 77:12479-12493. (Pubitemid 37430645)
45. Trkola A, Kuster H, Rusert P, Joos B, Fischer M, Leemann C, et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 2005; 11:615-622. (Pubitemid 40868301)
46. Borrow P, Shattock RJ, Vyakarnam A. EUROPRISE Working Group. Innate immunity against HIV: a priority target for HIV prevention research. Retrovirology 2010; 7:84.
47. Bostik P, Noble ES, Mayne AE, Gargano L, Villinger F, Ansari AA. Central memory CD4 T cells are the predominant cell subset resistant to anergy in SIV disease resistant sooty mangabeys. AIDS 2006; 20:181-188.
48. Autran B, Carcelain G, Combadiere B, Debre P. Therapeutic vaccines for chronic infections. Science 2004; 305:205-208. (Pubitemid 38886726)